This menu provides the list of EV proteins identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Protein name UniProt accession Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Isolation and identification of potential urinary microparticle biomarkers of bladder cancer.
J Proteome Res. 2008 May;7(5):2088-96. doi: 10.1021/pr700775x. Epub 2008 Mar 29.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Characterization of PKD protein-positive exosome-like vesicles.
J Am Soc Nephrol. 2009 Feb;20(2):278-88. doi: 10.1681/ASN.2008060564. Epub 2009 Jan 21.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature.
Mol Cell Proteomics. 2010 Feb;9(2):197-208. doi: 10.1074/mcp.M900152-MCP200. Epub 2009 Oct 16.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature.
Mol Cell Proteomics. 2010 Feb;9(2):197-208. doi: 10.1074/mcp.M900152-MCP200. Epub 2009 Oct 16.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Protein profile of exosomes from trabecular meshwork cells.
J Proteomics. 2011 May 16;74(6):796-804. doi: 10.1016/j.jprot.2011.02.024. Epub 2011 Mar 8.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of microvesicles derived from human colorectal cancer ascites.
Proteomics. 2011 Jul;11(13):2745-51. doi: 10.1002/pmic.201100022. Epub 2011 Jun 1.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of microvesicles derived from human mesenchymal stem cells.
J Proteome Res. 2012 Feb 3;11(2):839-49. doi: 10.1021/pr200682z. Epub 2011 Dec 28.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668The protein interaction network of extracellular vesicles derived from human colorectal cancer cells.
J Proteome Res. 2012 Feb 3;11(2):1144-51. doi: 10.1021/pr200842h. Epub 2012 Jan 9.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes.
Methods. 2012 Feb;56(2):293-304. doi: 10.1016/j.ymeth.2012.01.002. Epub 2012 Jan 21.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability.
J Proteomics. 2012 Jun 27;75(12):3574-84. doi: 10.1016/j.jprot.2012.03.054. Epub 2012 Apr 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668The proteome of erythrocyte-derived microparticles from plasma: new clues for erythrocyte aging and vesiculation.
J Proteomics. 2012 Dec 5;76 Spec No.:203-10. doi: 10.1016/j.jprot.2012.05.031. Epub 2012 Jun 2.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Biochemical and physical characterisation of urinary nanovesicles following CHAPS treatment.
PLoS One. 2012;7(7):e37279. doi: 10.1371/journal.pone.0037279. Epub 2012 Jul 12.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome.
Int J Proteomics. 2012;2012:971907. doi: 10.1155/2012/971907. Epub 2012 Jul 18.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.
Mol Cell Proteomics. 2013 Mar;12(3):587-98. doi: 10.1074/mcp.M112.021303. Epub 2012 Dec 10.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.
J Proteomics. 2013 Apr 26;82:193-229. doi: 10.1016/j.jprot.2013.01.012. Epub 2013 Jan 30.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668A comprehensive characterization of membrane vesicles released by autophagic human endothelial cells.
Proteomics. 2013 Apr;13(7):1108-20. doi: 10.1002/pmic.201200531.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components.
Proteomics. 2013 May;13(10-11):1672-86. doi: 10.1002/pmic.201200562.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic characterization of human platelet-derived microparticles.
Anal Chim Acta. 2013 May 7;776:57-63. doi: 10.1016/j.aca.2013.03.023. Epub 2013 Mar 19.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668LRRK2 secretion in exosomes is regulated by 14-3-3.
Hum Mol Genet. 2013 Dec 15;22(24):4988-5000. doi: 10.1093/hmg/ddt346. Epub 2013 Jul 25.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma.
Proteomics. 2013 Nov;13(22):3354-64. doi: 10.1002/pmic.201300282. Epub 2013 Oct 18.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma.
Proteomics. 2013 Nov;13(22):3354-64. doi: 10.1002/pmic.201300282. Epub 2013 Oct 18.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem Biophys Res Commun. 2014 Mar 21;445(4):694-701. doi: 10.1016/j.bbrc.2013.12.070. Epub 2014 Jan 14.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Plasma biomarker discovery in preeclampsia using a novel differential isolation technology for circulating extracellular vesicles.
Am J Obstet Gynecol. 2014 Mar 18. pii: S0002-9378(14)00248-8. doi: 10.1016/j.ajog.2014.03.038.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Discovery of prognostic biomarker candidates of lacunar infarction by quantitative proteomics of microvesicles enriched plasma.
PLoS One. 2014 Apr 21;9(4):e94663. doi: 10.1371/journal.pone.0094663. eCollection 2014.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
J Proteomics. 2014 Jun 25;106:191-204. doi: 10.1016/j.jprot.2014.04.028. Epub 2014 Apr 24.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Antibody-coupled monolithic silica microtips for highthroughput molecular profiling of circulating exosomes.
Sci Rep. 2014 Aug 29;4:6232. doi: 10.1038/srep06232.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication.
Mol Cell Proteomics. 2014 Sep 30. pii: mcp.M114.041194.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.
Oncotarget. 2015 Apr 12.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.
Oncotarget. 2015 Apr 12.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosome enrichment of human serum using multiple cycles of centrifugation.
Electrophoresis. 2015 May 23. doi: 10.1002/elps.201500131.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomes released by keratinocytes modulate melanocyte pigmentation.
Nat Commun. 2015 Jun 24;6:7506. doi: 10.1038/ncomms8506.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomal clusterin, identified in the pericardial fluid, improves myocardial performance following MI through epicardial activation, enhanced arteriogenesis and reduced apoptosis.
Int J Cardiol. 2015 Jun 14;197:333-347. doi: 10.1016/j.ijcard.2015.06.008.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Triple SILAC quantitative proteomic analysis reveals differential abundance of cell signaling proteins between normal and lung cancer-derived exosomes.
J Proteomics. 2015 Dec 28. pii: S1874-3919(15)30222-0. doi: 10.1016/j.jprot.2015.12.023.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes.
Proc Natl Acad Sci U S A. 2016 Feb 8. pii: 201521230.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15719-28. eCollection 2015.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Effective isolation of exosomes with polyethylene glycol from cell culture supernatant for in-depth proteome profiling.
Analyst. 2016 May 27.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis.
Clin Chim Acta. 2016 Sep 5. pii: S0009-8981(16)30375-8. doi: 10.1016/j.cca.2016.09.001.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis.
Clin Chim Acta. 2016 Sep 5. pii: S0009-8981(16)30375-8. doi: 10.1016/j.cca.2016.09.001.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of neuromyelitis optica and multiple sclerosis.
Clin Chim Acta. 2016 Sep 5. pii: S0009-8981(16)30375-8. doi: 10.1016/j.cca.2016.09.001.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic and bioinformatic characterization of extracellular vesicles released from human macrophages upon influenza A virus infection.
J Proteome Res. 2016 Oct 11.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression.
Eur J Pharm Sci. 2016 Oct 14. pii: S0928-0987(16)30431-6. doi: 10.1016/j.ejps.2016.10.008.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression.
Eur J Pharm Sci. 2016 Oct 14. pii: S0928-0987(16)30431-6. doi: 10.1016/j.ejps.2016.10.008.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression.
Eur J Pharm Sci. 2016 Oct 14. pii: S0928-0987(16)30431-6. doi: 10.1016/j.ejps.2016.10.008.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Mycobacterium tuberculosis Infection Manipulates the Glycosylation Machinery and the N-Glycoproteome of Human Macrophages and their Microparticles.
J Proteome Res. 2016 Oct 19.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Mycobacterium tuberculosis Infection Manipulates the Glycosylation Machinery and the N-Glycoproteome of Human Macrophages and their Microparticles.
J Proteome Res. 2016 Oct 19.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers.
PLoS One. 2017 Jun 8;12(6):e0178601. doi: 10.1371/journal.pone.0178601. eCollection 2017.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers.
PLoS One. 2017 Jun 8;12(6):e0178601. doi: 10.1371/journal.pone.0178601. eCollection 2017.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Proteomic analysis of neuroblastoma-derived exosomes: new insights into a metastatic signature.
Proteomics. 2017 Jul 19. doi: 10.1002/pmic.201600430.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Insulin mediated activation of PI3K/Akt signalling pathway modifies the proteomic cargo of extracellular vesicles.
Proteomics. 2017 Aug 26. doi: 10.1002/pmic.201600371.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Insulin mediated activation of PI3K/Akt signalling pathway modifies the proteomic cargo of extracellular vesicles.
Proteomics. 2017 Aug 26. doi: 10.1002/pmic.201600371.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
Ann Oncol. 2017 Sep 25. doi: 10.1093/annonc/mdx542.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Tetraspanin CD63 bridges autophagic and endosomal processes to regulate exosomal secretion and intracellular signaling of Epstein-Barr virus LMP1.
J Virol. 2017 Dec 6. pii: JVI.01969-17. doi: 10.1128/JVI.01969-17.
ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6C (Cytokeratin-6C) (CK-6C) (Cytokeratin-6E) (CK-6E) (Keratin K6h) (Keratin-6C) (K6C) (Type-II keratin Kb12)P48668Tetraspanin CD63 bridges autophagic and endosomal processes to regulate exosomal secretion and intracellular signaling of Epstein-Barr virus LMP1.
J Virol. 2017 Dec 6. pii: JVI.01969-17. doi: 10.1128/JVI.01969-17.
ENOG410YY6B437 / 0 / 437
[1]